HER2 NEGATIVE BREAST CANCER

HER2 NEGATIVE BREAST CANCER was reported 51 times

HER2 NEGATIVE BREAST CANCER is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Estrogen Receptor Antagonist [EPC] 8 0.0002
1 Aromatase Inhibitor [EPC] 17 0.0001
2 HER2/neu Receptor Antagonist [EPC] 7 0.0001
3 Microtubule Inhibitor [EPC] 5 0.0000
4 Interleukin-17A Antagonist [EPC] 1 0.0000
5 RANK Ligand Inhibitor [EPC] 4 0.0000
6 Macrolide Antimicrobial [EPC] 1 0.0000
7 Estrogen [EPC] 3 0.0000
8 Platinum-based Drug [EPC] 3 0.0000
9 Nucleoside Metabolic Inhibitor [EPC] 3 0.0000
10 Kinase Inhibitor [EPC] 4 0.0000
11 Leukocyte Growth Factor [EPC] 1 0.0000
12 Vascular Endothelial Growth Factor Inhibitor [EPC] 1 0.0000
13 Thiazide Diuretic [EPC] 1 0.0000
14 Vitamin D [EPC] 1 0.0000
15 CD20-directed Cytolytic Antibody [EPC] 1 0.0000
16 Vitamin B12 [EPC] 1 0.0000
17 Vitamin C [EPC] 1 0.0000
18 Tumor Necrosis Factor Blocker [EPC] 1 0.0000